Retatrutide vs Orforglipron: Injectable Triple Agonist vs Oral GLP-1

Retatrutide and orforglipron are both made by Eli Lilly, but they represent completely different approaches to obesity treatment. Retatrutide is an injectable triple agonist targeting three receptors for maximum weight loss. Orforglipron is an oral daily pill targeting one receptor for maximum convenience — no needles, no fasting, no food restrictions.

The trade-off is clear: retatrutide produces nearly 2.5 times more weight loss than orforglipron, but orforglipron eliminates the injection barrier that deters many patients from starting treatment.

Side-by-Side Comparison

	Retatrutide	Orforglipron
Delivery	Once-weekly injection	Once-daily oral pill
Molecule type	Peptide (injectable)	Small molecule, non-peptide (oral)
Receptors	GLP-1 + GIP + Glucagon (triple agonist)	GLP-1 only (single agonist)
Max weight loss	-28.7% at 68 weeks (TRIUMPH-4)	-12.4% at 72 weeks (ATTAIN-1)
Max dose	12 mg weekly	36 mg daily
Food restrictions	None	None (unlike oral semaglutide/Rybelsus)
FDA timeline	Expected ~2027	Expected March 2026
GI discontinuation	12-18%	5.3-10.3%
Unique signal	Dysesthesia (8.8-20.9%)	None beyond GI class effects
Projected 2031 sales	$30 billion	$16 billion

How the Mechanisms Differ

Orforglipron: One Receptor, Oral Delivery

Orforglipron (LY3502970) is a non-peptide, small-molecule GLP-1 receptor agonist. Unlike injectable GLP-1 drugs (which are peptides that would be destroyed by stomach acid), orforglipron is a small molecule that acts as an allosteric agonist — it binds within a transmembrane pocket on the GLP-1 receptor, distinct from where the natural GLP-1 hormone binds, and stabilizes an active receptor conformation.

Because it is a small molecule, orforglipron is:

Chemically stable in stomach acid — no special coating or absorption enhancers needed
Resistant to digestive enzymes (DPP-4 and proteases) that would destroy peptide drugs
Taken any time of day without fasting or food/water restrictions

This is a significant advantage over oral semaglutide (Rybelsus), which requires 30 minutes of fasting with minimal water.

Retatrutide: Three Receptors, Maximum Efficacy

Retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously. The additional GIP and glucagon pathways drive substantially more weight loss. The glucagon component in particular increases resting energy expenditure through thermogenesis — your body burns more calories at rest — and promotes liver fat oxidation.

For details on each receptor, see What Is Retatrutide (GLP-3)?.

Weight Loss Comparison

Drug	Trial	Duration	Max Weight Loss
Retatrutide 12 mg	TRIUMPH-4 (Phase 3)	68 weeks	-28.7%
Orforglipron 36 mg	ATTAIN-1 (Phase 3)	72 weeks	-12.4%
Orforglipron 36 mg (T2D)	ATTAIN-2 (Phase 3)	72 weeks	-10.5%

Retatrutide's weight loss is approximately 2.3 times greater than orforglipron at comparable timepoints. This is consistent with the pattern seen across GLP-1 drugs: single agonists produce ~12-17% weight loss, dual agonists ~22%, and the triple agonist ~29%.

Weight Loss Thresholds (Orforglipron, ATTAIN-1)

Threshold	Orforglipron 36 mg	Placebo
Lost at least 10%	59.6%	—
Lost at least 15%	39.6%	—

Switching Between the Two

Lilly's ATTAIN-MAINTAIN trial demonstrated that patients switching from injectable incretins (semaglutide or tirzepatide) to oral orforglipron maintained most of their prior weight loss. Average differences were only 0.9 kg from semaglutide and 5.0 kg from tirzepatide over 52 weeks. This suggests orforglipron could serve as a maintenance option after achieving weight loss on injectable drugs — though switching from retatrutide to orforglipron has not been studied.

Side Effects and Tolerability

	Retatrutide	Orforglipron
Most common	Nausea, diarrhea, constipation, vomiting	Diarrhea, nausea, constipation, vomiting, dyspepsia
Severity	Mostly mild-moderate	Mostly mild-moderate
Discontinuation (AEs)	12-18%	5.3-10.3% (vs 2.7% placebo)
Unique signal	Dysesthesia (tingling/burning) in 8.8-20.9%	None beyond GI class effects
Notable absence	—	No pancreatitis, retinal, or optic signals

Orforglipron has a lower discontinuation rate than retatrutide, and GI side effects typically improve within 4-8 weeks during dose escalation. Orforglipron's Phase 3 data notably showed no signals for pancreatitis, retinal detachment, or ischemic optic neuropathy.

FDA Timeline

Milestone	Orforglipron	Retatrutide
NDA submitted	Late 2025 (obesity)	Not yet filed
FDA review	Granted National Priority Voucher	Standard review expected
Expected approval	March 2026	~2027
Diabetes filing	Planned 2026	Pending TRANSCEND data

Orforglipron received the FDA Commissioner's National Priority Voucher, which could shorten review from the standard 10-12 months to potentially 1-2 months. This would make it the second oral GLP-1 approved for obesity (after Novo Nordisk's oral Wegovy).

Lilly's Portfolio Strategy

Eli Lilly is developing both drugs because they serve different patient needs:

Orforglipron — for patients who prefer or need oral therapy, needle-phobic patients, maintenance therapy after initial injectable weight loss, or patients who need moderate weight loss (~12%)
Retatrutide — for patients seeking maximum weight loss, those with comorbidities like fatty liver disease or knee osteoarthritis where the glucagon mechanism adds specific benefit

The two drugs are complementary, not competing. Analysts project combined 2031 sales of ~$46 billion ($30B retatrutide + $16B orforglipron).

Frequently Asked Questions

Is retatrutide better than orforglipron?

Retatrutide produces substantially more weight loss (-28.7% vs -12.4%). However, orforglipron offers the convenience of an oral pill with no injections. The best choice depends on individual goals, needle tolerance, and medical needs. Both drugs are still investigational.

Why does orforglipron produce less weight loss?

Orforglipron activates only one receptor (GLP-1), while retatrutide activates three (GLP-1, GIP, glucagon). The additional receptors drive significantly more weight loss. This follows the consistent pattern: more receptor targets correlate with greater weight loss across all incretin drugs studied.

Can I take orforglipron as a pill while waiting for retatrutide?

If orforglipron is approved (expected March 2026), it could be an option while waiting for retatrutide (~2027). Discuss this with your doctor. The ATTAIN-MAINTAIN trial suggests that switching between oral and injectable incretins is feasible.

Will Lilly make a retatrutide pill?

There is no announced plan for an oral retatrutide. Retatrutide is a peptide that requires injection. Developing an oral version would face significant technical challenges due to its large molecular size and triple receptor binding requirements. See Retatrutide Pill vs Injection.

Sources

Eli Lilly. (2025). ATTAIN-1 Phase 3 results. Press release.
Wharton, S., et al. (2025). Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. NEJM. DOI: 10.1056/NEJMoa2511774
Eli Lilly. (2025). ATTAIN-MAINTAIN results. Press release.
Eli Lilly. (2025). TRIUMPH-4 results. Press release.

How we keep this honest

What this is: Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status: Retatrutide and similar peptides are investigational — not approved by the FDA or any regulator. Semaglutide and tirzepatide are prescription-only medicines, available only through a licensed prescriber.
Our standard: Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties: We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Sources